Legal Battle Between UCSD, USC Continues

The University of Southern California countersues the University of California, San Diego, as a pharmaceutical company ends an Alzheimer’s research–related contract with the latter institution.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The George Finley Bovard building on the campus of USCWIKIMEDIA, BRION VIBBERThe legal dispute between the University of Southern California (USC) and the University of California, San Diego (UCSD), is showing no signs of resolution. Last month (August 24), a San Diego Superior Court Judge issued a preliminary injunction that would force USC to cede control of a multi-million-dollar Alzheimer’s project that a former UCSD researcher took with him when he moved institutions. And as the two sides await the formal court order granting the injunction, USC countersued UCSD for trying to intimidate researchers who also wanted to leave UCSD for USC with principal investigator Paul Aisen, among other allegations.

“The University of Southern California’s cross-complaint is fundamentally dishonest,” UCSD said in a statement. “It is a collection of misstatements and outright falsehoods designed to distract from a singular truth: While he was on the faculty at UC San Diego, Dr. Paul Aisen, aided and abetted by his future employer USC, illegally seized control of data and computer systems that belong to UC San Diego as the administrator of the Alzheimer’s Disease Cooperative Study (ADCS).”

In its countersuit, USC is claiming that UCSD tried to force Aisen to sign an oath of loyalty prior to his departure from UCSD to USC in June. The suit also alleges that UCSD defamed Aisen by telling pharmaceutical industry sponsors of ADCS that Aisen had committed crimes and was ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies